ProfileGDS5678 / 1420108_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 61% 60% 60% 57% 61% 63% 64% 60% 59% 60% 60% 60% 61% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.6922961
GSM967853U87-EV human glioblastoma xenograft - Control 23.5797560
GSM967854U87-EV human glioblastoma xenograft - Control 33.5806960
GSM967855U87-EV human glioblastoma xenograft - Control 43.4198957
GSM967856U87-EV human glioblastoma xenograft - Control 53.5954461
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.825163
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8754364
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.5681460
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5151959
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5614360
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.5827860
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5508660
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.6428161
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5848160